Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Omicron COVID-19 Inactivated Vaccine in Unvaccinated Adults
NCT05365724Phase 2Unknown
- Sponsor
- China National Biotec Group
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of inactivated COVID-19 vaccine (Omicron variant) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by China National Biotec Group. Primary endpoints: Geometric Mean Titer of neutralizing antibody against Omicron SARS-CoV-2, Four-fold increase rate of neutralizing antibody against Omicron SARS-CoV-2 and 1 more. Status: unknown.
02
Drugs
inactivated COVID-19 vaccine (Omicron variant)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05365724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365724.